UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
| | | |
| (Commission File Number) | (IRS Employer Identification No.) | |
| | | |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| | |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 1.01 |
Entry into a Material Definitive Agreement. |
On July 15, 2022, Meizhong Health Industry Development Co., Ltd. (“Meizhong Health”), a wholly owned subsidiary of America Great Health entered into a Cooperation Agreement (the “Agreement”) with Nanjing Zansheng Enterprise Service Center. (“Nanjing Zansheng”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purposes of fundraising and promoting oral insulin-related products, as well as developing new oral insulin drugs. Nanjing Zansheng shall invest one million RMB in the JV Company as registered capital, to account for 49% equity ownership of the JV Company; MeiZhong Health shall transfer and invest its oral insulin-related technologies, which is patent pending, into the JV Company as its capital contribution, to account for 51% equity ownership of the JV Company. Meizhong Health shall designate a person to act as general manager of the new company, who shall be responsible for the JV Company’s operations and management.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. Differences may result from risks and uncertainties beyond the Company’s control. Additional factors that could materially impact the Company’s results and operations can be found under the caption “Risk Factors” in Zillow Group, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2015 and in the Company’s other filings with the Securities and Exchange Commission. Except as may be required by law, Zillow Group does not intend, nor undertake any duty, to update this information to reflect future events or circumstances.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: August 01, 2022
By: /s/ Mike Wang
Name: Mike Wang
Title: President